Merck KGaA’s MilliporeSigma invests $286M to build out biosafety testing
MilliporeSigma, the US and Canadian life science division of Merck KGaA, is plunking down almost $300 million to boost biosafety testing in the US.
The company said it will invest $286 million to bulk up biosafety testing at its manufacturing site in Rockville, MD. The new, 250,000-square-foot facility expansion will extend its capacity for biosafety testing, analytical development, viral clearance suites and services for cell bank manufacturing. MilliporeSigma didn’t detail project timeline in its announcement and did not responded to a request for comment from Endpoints News by press time.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.